Madison Area Lyme Support Group

Today’s letter… The Oregon Public Broadcasting interview below with Winslow Crane-Murdoch, co-director of the Quiet Epidemic is worth the read.

https://www.opb.org/article/2023/03/08/lyme-disease-quiet-epidemic-documentary/

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “thinkoutloud@opb.org” <thinkoutloud@opb.org>
Cc: “dmiller@opb.org” <dmiller@opb.org>, “opbnews@opb.org” <opbnews@opb.org>, “svanwing@opb.org” <svanwing@opb.org>, “mholm@opb.org” <mholm@opb.org>, “abarrett@utmb.edu” <abarrett@utmb.edu>, “R.W.Titball@exeter.ac.uk” <R.W.Titball@exeter.ac.uk>, “kait@thequietepidemic.com” <kait@thequietepidemic.com>, “lindsay@thequietepidemic.com” <lindsay@thequietepidemic.com>, “Raymond_Dattwyler@nymc.edu” <Raymond_Dattwyler@nymc.edu>
Date: 03/22/2023 9:27 AM

Subject: THINK OUT LOUD; New documentary explores Lyme disease controversies

New documentary explores Lyme disease controversies
https://www.opb.org/article/2023/03/08/lyme-disease-quiet-epidemic-documentary/
By Sage Van Wing (OPB)  March 8, 2023

“The medical community has been slow to recognize this form of long-lasting [Chronic] Lyme disease and to find treatments for it”

Oregon Public Broadcasting
THINK OUT LOUD
Attn: Dave Miller, Host

Dear Mr. Miller,

Thank you for interviewing Winslow Crane-Murdoch, co-director of the Quiet Epidemic.

I spent the last thirteen years studying the mishandling of Lyme disease as an independent researcher whose entire family progressed to late-stage Lyme before we knew what went wrong with our health. I can say with 100% confidence that the rush to create a vaccine led to the denial of persistent infection after the one-size-fits-all IDSA treatment guideline; chronic Lyme disease.

Please see the inquiry below addressed to Dr. Raymond Dattwyler who owns 24 patents that include diagnostic testing and Lyme vaccines (OspA) both live bacteria and oral. Maria Gomes-Solecki (co-author of this publication) is co-owner to 17 of those patents.

A new OspA vaccine has been fast tracked by the FDA. The previous OspA vaccine LYMErix was pulled from the market in 2002 not solely due to low demand per the following report.

REPORT ON LYMErix prepared for the 2001 Advisory Committee Meeting:(personal Dropbox storage area)
https://www.dropbox.com/s/sodqs3pdeeesktf/Sheller%20Lymerix.pdf?dl=0

Excerpt

“The people who have contacted us were, prior to vaccination with LYMErix, healthy, active and energetic. Indeed, the very reason they sought the LYMErix vaccine was their desire to preserve their healthy, active lifestyle. However, what they experienced was a dramatic degradation of their health and quality of life. As will be described below, these previously healthy individuals are now afflicted with painful, at times debilitating arthritic symptoms, including joint pain and swelling, as well as extremely severe Lyme-disease-like symptoms which have persisted to this day.”

Below is the link to the Final Judgement and Approval of the class action against SmithKline Beecham as a settlement was awarded to these individuals.

JUDGEMENT, FINAL ORDER AND DECREE GRANTING FINAL APPROVAL OF THE CLASS ACTION SETTLEMENT: (personal Dropbox storage area)
https://www.dropbox.com/s/v3gyw4fv8nst9bz/2003_Vaccine_Judgement_Final_Sttle_Apprvl..pdf?dl=0

In addition, there were neurological complications with LYMErix as published in the International Journal of Risk & Safety in Medicine. Reports of cerebral ischemia, transient Ischemic attacks, demyelinating events, optic neuritis, transverse myelitis, and non-specific demyelinating conditions are evaluated in this paper:

Neurological complications of vaccination with outer surface protein A (OspA).
Marks DH
http://www.ncbi.nlm.nih.gov/pubmed/21673416

2023 Announcement for the current OspA vaccine: (is history about to repeat itself?)

Western New York kids are eligible to get a Lyme disease vaccine through Pfizer clinical study conducted at UB
https://www.buffalo.edu/news/releases/2023/03/015.html

Mr. Miller,

An astute fifth grader with access to PubMed could find the references I provided to Dr. Dattwyler in my email below.

A chronic relapsing seronegative disease does not fit the business model of vaccine development, patent royalties and pharmaceutical profits. You cannot prove vaccine efficacy when we do not know who has or does not have the disease.

For the record, Dattwyler refused to respond to my inquiry so perhaps you could reach out to him for comment. I have taken the liberty to carbon copy Dr. Dattwyler along with Alan D.T. Barrett, PhD Editor-in-Chief of npj Vaccines.

Respectfully submitted,

Carl Tuttle
Hudson, NH

Inquiry to Dr. Raymond Dattwyler:

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: Raymond_Dattwyler@nymc.edu
Cc: npjvaccines@nature.com, abarrett@utmb.edu, R.W.Titball@exeter.ac.uk, mgomesso@uthsc.edu
Date: 01/06/2023 2:46 PM
Subject: The year that shaped the outcome of the OspA vaccine for human Lyme disease

npj Vaccines Jan 2022

The year that shaped the outcome of the OspA vaccine for human Lyme disease
https://www.nature.com/articles/s41541-022-00429-5
Raymond J. Dattwyler & Maria Gomes-Solecki

Department of Microbiology and Immunology
New York Medical College
Valhalla, NY
Raymond J. Dattwyler, Corresponding Author

Dear Dr. Dattwyler,

I read your manuscript with great interest as you call attention to a treatment-resistant Lyme arthritis with “no evidence of DNA” found in the joints of patients after antibiotic treatment.

For some strange reason however, I could not find the following 1995 publication within your paper identifying treatment-resistant neuroborreliosis:

European Neurology 1995

Seronegative Chronic Relapsing Neuroborreliosis
https://www.karger.com/Article/Abstract/117104

Lawrence C., Lipton R.B., Lowy F.D., Coyle P.K.d

Abstract

We report an unusual patient with evidence of Borrelia burgdorferi infection who experienced repeated neurologic relapses despite aggressive antibiotic therapy. Each course of therapy was associated with a Jarisch-Herxheimer-like reaction. Although the patient never had detectable free antibodies to B. burgdorferi in serum or spinal fluid, the CSF was positive on multiple occasions for complexed anti-B. burgdorferi antibodies, B. burgdorferi nucleic acids and free antigen.

In fact, Dr. Dattwyler there seems to be a great deal of “treatment-resistant” evidence published in multiple journals over the past three decades:

Peer Reviewed Evidence of Persistence of Lyme Disease Spirochete Borrelia burgdorferi and Tick-Borne Diseases (700 References)
https://www.dropbox.com/s/n09sk90eo6xz7ua/700%20articles%20LYME%20EvidenceofPersistence-V2.pdf?dl=0

So that brings me to the reason for this email…

Question:  Does a chronic relapsing seronegative disease fit the vaccine model? If not, would that, in and of itself, be the hidden reason for denying chronic (treatment-resistant) Lyme disease for almost three decades?  In other words, patent royalties and pharmaceutical profits over lifesaving care?

A response to this inquiry is requested.

Carl Tuttle
Hudson, NH

Cc: Alan D.T. Barrett, PhD Editor-in-Chief
Rick Titball, PhD, DSc, Deputy Editor

Letter to the Editor of the BMJ published June 2020
https://www.bmj.com/content/369/bmj.m1041/rr-1